{"transactions":[{"id":794158,"issuer":{"id":4799,"kind":"organization","name":"Seaport Therapeutics, Inc."},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T22:00:47.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":49033,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying this option shall vest and become exercisable on April 30, 2027, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":49033,"derivative":{"exercise_price":18,"expiration_date":"2036-04-29","underlying":"Common Stock","underlying_shares":49033},"source":{"system":"sec-edgar","filing":"0001193125-26-204449","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526204449/ownership.xml","form_type":"4"}},{"id":931209,"issuer":{"id":5596,"kind":"organization","name":"Benitec Biopharma Inc."},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (right to buy)","published_at":"2026-01-26T21:10:15.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026."}],"balance_after":31500,"derivative":{"exercise_price":12.83,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001012975-26-000082","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808898/000101297526000082/form4.xml","form_type":"4"}},{"id":981675,"issuer":{"id":5596,"kind":"organization","name":"Benitec Biopharma Inc."},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (right to buy)","published_at":"2025-12-03T21:20:40.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026."}],"balance_after":3500,"derivative":{"exercise_price":12.23,"expiration_date":"2035-12-01","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001012975-25-000851","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808898/000101297525000851/form4.xml","form_type":"4"}},{"id":1004934,"issuer":{"id":5596,"kind":"organization","name":"Benitec Biopharma Inc."},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (right to buy)","published_at":"2025-11-08T00:50:02.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":28517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options will vest in full on the earlier of immediately prior to the Issuer's 2026 annual meeting of stockholders and November 5, 2026."}],"balance_after":28517,"derivative":{"exercise_price":15.78,"expiration_date":"2035-11-05","underlying":"Common Stock","underlying_shares":28517},"source":{"system":"sec-edgar","filing":"0001012975-25-000718","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808898/000101297525000718/form4.xml","form_type":"4"}},{"id":1182656,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34970,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":34970},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182655,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":34970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":34970,"derivative":{"underlying":"Common Stock","underlying_shares":34970},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182654,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40712,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40712},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182653,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Performance Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"grant","planned":false,"acquired":true,"shares":40712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":40712,"derivative":{"underlying":"Common Stock","underlying_shares":40712},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182652,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121212,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":121212},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182651,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":69940,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":69940},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182650,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40713,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit (each, a \"Company RSU\") and each performance-based restricted stock unit (each, a \"Company PRSU\") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40713},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182649,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":56.73,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":50167},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182648,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53471,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":36.89,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":53471},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182647,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":66886,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":23.94,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":66886},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182646,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":138473,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.47,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":138473},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182645,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135399,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.73,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":135399},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182644,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86003,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":53.63,"expiration_date":"2026-01-03","underlying":"Common Stock","underlying_shares":86003},"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182643,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":190000,"price":132,"value":25080000.0,"ownership":{"direct":false,"nature":"By the Sharon Mates Family Foundation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by the Sharon Mates Family Foundation (the \"Foundation\"). The reporting person disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1182642,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-04-02T17:30:39.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":945235,"price":132,"value":124771020.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-049595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025049595/ownership.xml","form_type":"4"}},{"id":1187707,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-31T18:01:05.000Z","date":"2025-03-26","kind":"gift","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Sharon Mates Family Foundation"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed to report a transfer of shares from the reporting person to the Sharon Mates Family Foundation as a bona fide gift for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by the Sharon Mates Family Foundation (the \"Foundation\"). The reporting person disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any."}],"balance_after":190000,"source":{"system":"sec-edgar","filing":"0000950170-25-047937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025047937/ownership.xml","form_type":"4"}},{"id":1187706,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-31T18:01:05.000Z","date":"2025-03-26","kind":"gift","planned":false,"acquired":false,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed to report a transfer of shares from the reporting person to the Sharon Mates Family Foundation as a bona fide gift for no consideration."}],"balance_after":945235,"source":{"system":"sec-edgar","filing":"0000950170-25-047937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025047937/ownership.xml","form_type":"4"}},{"id":1214525,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-10T18:01:06.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":false,"shares":20566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20566},"source":{"system":"sec-edgar","filing":"0000950170-25-036593","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036593/ownership.xml","form_type":"4"}},{"id":1214524,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-10T18:01:06.000Z","date":"2025-03-06","kind":"exercise","planned":false,"acquired":false,"shares":40712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":40713,"derivative":{"underlying":"Common Stock","underlying_shares":40712},"source":{"system":"sec-edgar","filing":"0000950170-25-036593","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036593/ownership.xml","form_type":"4"}},{"id":1214523,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:06.000Z","date":"2025-03-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":10129,"price":131.24,"value":1329329.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person."}],"balance_after":1135235,"source":{"system":"sec-edgar","filing":"0000950170-25-036593","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036593/ownership.xml","form_type":"4"}},{"id":1214522,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:06.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":true,"shares":20566,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1145364,"source":{"system":"sec-edgar","filing":"0000950170-25-036593","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036593/ownership.xml","form_type":"4"}},{"id":1214521,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:06.000Z","date":"2025-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":19848,"price":131.19,"value":2603859.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person."}],"balance_after":1124798,"source":{"system":"sec-edgar","filing":"0000950170-25-036593","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036593/ownership.xml","form_type":"4"}},{"id":1214520,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-10T18:01:06.000Z","date":"2025-03-06","kind":"exercise","planned":false,"acquired":true,"shares":40712,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1144646,"source":{"system":"sec-edgar","filing":"0000950170-25-036593","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025036593/ownership.xml","form_type":"4"}},{"id":1226532,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-04T18:01:09.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":false,"shares":34969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 1, 2024, the reporting person was granted 104,909 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 1, 2024, the reporting person was granted 104,909 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":69940,"derivative":{"underlying":"Common Stock","underlying_shares":34969},"source":{"system":"sec-edgar","filing":"0000950170-25-032587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025032587/ownership.xml","form_type":"4"}},{"id":1226531,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-04T18:01:09.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":16978,"price":128.2,"value":2176579.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person."}],"balance_after":1103934,"source":{"system":"sec-edgar","filing":"0000950170-25-032587","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025032587/ownership.xml","form_type":"4"}},{"id":1226530,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-03-04T18:01:09.000Z","date":"2025-03-01","kind":"exercise","planned":false,"acquired":true,"shares":34969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1120912,"source":{"system":"sec-edgar","filing":"0000950170-25-032587","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025032587/ownership.xml","form_type":"4"}},{"id":1283809,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T17:32:10.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":121212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 3, 2025, the reporting person was granted 121,212 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 3, 2025, the reporting person was granted 121,212 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":121212,"derivative":{"underlying":"Common Stock","underlying_shares":121212},"source":{"system":"sec-edgar","filing":"0000950170-25-013765","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025013765/ownership.xml","form_type":"4"}},{"id":1283808,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-02-04T17:32:10.000Z","date":"2025-01-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":15233,"price":127,"value":1934591.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the reporting person."}],"balance_after":1085943,"source":{"system":"sec-edgar","filing":"0000950170-25-013765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025013765/ownership.xml","form_type":"4"}},{"id":1283807,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2025-02-04T17:32:10.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":30847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 10, 2022, the reporting person was granted performance-based restricted stock units (\"PRSUs\") under the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan. Each PRSU represents a contingent right to receive one share of common stock upon vesting and settlement. On January 31, 2025, 30,847 PRSUs were vested upon achievement of the reporting person's performance criteria."}],"balance_after":1101176,"source":{"system":"sec-edgar","filing":"0000950170-25-013765","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017025013765/ownership.xml","form_type":"4"}},{"id":1340173,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-05","kind":"exercise","planned":true,"acquired":false,"shares":51697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-07","underlying":"Common Stock","underlying_shares":51697},"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340172,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-04","kind":"exercise","planned":true,"acquired":false,"shares":51000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares underlying this option have vested."}],"balance_after":51697,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-07","underlying":"Common Stock","underlying_shares":51000},"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340171,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-05","kind":"sale","planned":true,"acquired":false,"shares":1534,"price":84.6897,"value":129913.9998,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.56 to $85.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340170,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-05","kind":"sale","planned":true,"acquired":false,"shares":50163,"price":84.0645,"value":4216927.5135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1071863,"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340169,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-05","kind":"exercise","planned":true,"acquired":true,"shares":51697,"price":12.73,"value":658102.81,"ownership":{"direct":true},"balance_after":1122026,"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340168,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-04","kind":"sale","planned":true,"acquired":false,"shares":23333,"price":86.0048,"value":2006749.9984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.91 to $86.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340167,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-04","kind":"sale","planned":true,"acquired":false,"shares":27667,"price":85.6222,"value":2368909.4074,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.91 to $85.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1093662,"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1340166,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-12-06T18:01:05.000Z","date":"2024-12-04","kind":"exercise","planned":true,"acquired":true,"shares":51000,"price":12.73,"value":649230.0,"ownership":{"direct":true},"balance_after":1121329,"source":{"system":"sec-edgar","filing":"0000950170-24-134240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024134240/ownership.xml","form_type":"4"}},{"id":1418799,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-30","kind":"exercise","planned":true,"acquired":false,"shares":34396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares underlying this option have vested."}],"balance_after":102697,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-07","underlying":"Common Stock","underlying_shares":34396},"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418798,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-29","kind":"exercise","planned":true,"acquired":false,"shares":35604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"All shares underlying this option have vested."}],"balance_after":137093,"derivative":{"exercise_price":12.73,"expiration_date":"2029-01-07","underlying":"Common Stock","underlying_shares":35604},"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418797,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-30","kind":"sale","planned":true,"acquired":false,"shares":6193,"price":73.3232,"value":454090.5776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.28 to $73.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418796,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-30","kind":"sale","planned":true,"acquired":false,"shares":28203,"price":72.732,"value":2051260.596,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.27 to $73.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1076522,"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418795,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-30","kind":"exercise","planned":true,"acquired":true,"shares":34396,"price":12.73,"value":437861.08,"ownership":{"direct":true},"balance_after":1104725,"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418794,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-29","kind":"sale","planned":true,"acquired":false,"shares":5772,"price":73.2451,"value":422770.7172,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.02 to $73.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418793,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-29","kind":"sale","planned":true,"acquired":false,"shares":29832,"price":72.4428,"value":2161113.6096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.02 to $73.015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1076101,"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1418792,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-30T18:01:46.000Z","date":"2024-08-29","kind":"exercise","planned":true,"acquired":true,"shares":35604,"price":12.73,"value":453238.92,"ownership":{"direct":true},"balance_after":1105933,"source":{"system":"sec-edgar","filing":"0000950170-24-102475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024102475/ownership.xml","form_type":"4"}},{"id":1420615,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-28","kind":"exercise","planned":true,"acquired":false,"shares":32699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":32699},"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420614,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-27","kind":"exercise","planned":true,"acquired":false,"shares":40513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":32699,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":40513},"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420613,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-26","kind":"exercise","planned":true,"acquired":false,"shares":22713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":73212,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":22713},"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420612,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-28","kind":"sale","planned":true,"acquired":false,"shares":240,"price":73.7,"value":17688.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420611,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-28","kind":"sale","planned":true,"acquired":false,"shares":32459,"price":72.7414,"value":2361113.1026,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.42 to $73.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070569,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420610,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-28","kind":"exercise","planned":true,"acquired":true,"shares":32699,"price":17.57,"value":574521.43,"ownership":{"direct":true},"balance_after":1103028,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420609,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-27","kind":"sale","planned":true,"acquired":false,"shares":16856,"price":73.9316,"value":1246191.0496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.88 to $74.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420608,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-27","kind":"sale","planned":true,"acquired":false,"shares":23657,"price":73.3341,"value":1734864.8037,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.88 to $73.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1087185,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420607,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-27","kind":"exercise","planned":true,"acquired":true,"shares":40513,"price":17.57,"value":711813.41,"ownership":{"direct":true},"balance_after":1110842,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420606,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-26","kind":"sale","planned":true,"acquired":false,"shares":22713,"price":74.5929,"value":1694228.5377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.35 to $75.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1420605,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-28T18:00:57.000Z","date":"2024-08-26","kind":"exercise","planned":true,"acquired":true,"shares":22713,"price":17.57,"value":399067.41,"ownership":{"direct":true},"balance_after":1093042,"source":{"system":"sec-edgar","filing":"0000950170-24-101506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024101506/ownership.xml","form_type":"4"}},{"id":1424033,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-23","kind":"exercise","planned":true,"acquired":false,"shares":28680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":95925,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":28680},"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424032,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-22","kind":"exercise","planned":true,"acquired":false,"shares":39380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":124605,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":39380},"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424031,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-21","kind":"exercise","planned":true,"acquired":false,"shares":53013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":163985,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":53013},"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424030,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-23","kind":"sale","planned":true,"acquired":false,"shares":28680,"price":74.4573,"value":2135435.364,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.16 to $74.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424029,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-23","kind":"exercise","planned":true,"acquired":true,"shares":28680,"price":17.57,"value":503907.6,"ownership":{"direct":true},"balance_after":1099009,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424028,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-22","kind":"sale","planned":true,"acquired":false,"shares":4369,"price":75.4697,"value":329727.1193,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.30 to $75.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424027,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-22","kind":"sale","planned":true,"acquired":false,"shares":35011,"price":74.5787,"value":2611074.8657,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.28 to $75.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1074698,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424026,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-22","kind":"exercise","planned":true,"acquired":true,"shares":39380,"price":17.57,"value":691906.6,"ownership":{"direct":true},"balance_after":1109709,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424025,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":77.9805,"value":148162.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.905 to $78.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424024,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":2682,"price":77.2139,"value":207087.6798,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.975 to $77.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1072229,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424023,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":4297,"price":76.2001,"value":327431.8297,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.90 to $76.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1074911,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424022,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":44134,"price":75.4026,"value":3327818.3484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1079208,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1424021,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-08-23T18:00:20.000Z","date":"2024-08-21","kind":"exercise","planned":true,"acquired":true,"shares":53013,"price":17.57,"value":931438.41,"ownership":{"direct":true},"balance_after":1123342,"source":{"system":"sec-edgar","filing":"0000950170-24-100275","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024100275/ownership.xml","form_type":"4"}},{"id":1535286,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-25T17:08:34.000Z","date":"2024-04-24","kind":"exercise","planned":false,"acquired":false,"shares":11382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested."}],"balance_after":216998,"derivative":{"exercise_price":17.57,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":11382},"source":{"system":"sec-edgar","filing":"0000950170-24-048467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024048467/ownership.xml","form_type":"4"}},{"id":1535285,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-25T17:08:34.000Z","date":"2024-04-24","kind":"exercise","planned":false,"acquired":false,"shares":8638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":16.86,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":8638},"source":{"system":"sec-edgar","filing":"0000950170-24-048467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024048467/ownership.xml","form_type":"4"}},{"id":1535284,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-04-25T17:08:34.000Z","date":"2024-04-24","kind":"exercise","planned":false,"acquired":true,"shares":11382,"price":17.57,"value":199981.74,"ownership":{"direct":true},"balance_after":1070329,"source":{"system":"sec-edgar","filing":"0000950170-24-048467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024048467/ownership.xml","form_type":"4"}},{"id":1535283,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-04-25T17:08:34.000Z","date":"2024-04-24","kind":"exercise","planned":false,"acquired":true,"shares":8638,"price":16.86,"value":145636.68,"ownership":{"direct":true},"balance_after":1058947,"source":{"system":"sec-edgar","filing":"0000950170-24-048467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024048467/ownership.xml","form_type":"4"}},{"id":1583636,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Restricted Stock Units","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-10","kind":"exercise","planned":true,"acquired":false,"shares":20565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"On March 10, 2022, the reporting person was granted 61,696 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":20566,"derivative":{"underlying":"Common Stock","underlying_shares":20565},"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583635,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":306,"price":67.33,"value":20602.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.32 to $67.3794, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1050309,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583634,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1590,"price":66.81,"value":106227.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.32 to $66.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1050615,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583633,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":4128,"price":65.9,"value":272035.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.51 to $66.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1052205,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583632,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":14541,"price":64.8,"value":942256.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.4977 to $65.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1056333,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583631,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-10","kind":"exercise","planned":true,"acquired":true,"shares":20565,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1070874,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583630,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":8754,"price":66.93,"value":585905.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.8069 to $67.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1050309,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1583629,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-11T20:33:20.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":31958,"price":66.38,"value":2121372.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.81 to $66.7893, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1059063,"source":{"system":"sec-edgar","filing":"0000950170-24-029583","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024029583/ownership.xml","form_type":"4"}},{"id":1586035,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Restricted Stock Units","published_at":"2024-03-08T17:59:02.000Z","date":"2024-03-06","kind":"exercise","planned":false,"acquired":false,"shares":40712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 6, 2023, the reporting person was granted 122,137 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":81425,"derivative":{"underlying":"Common Stock","underlying_shares":40712},"source":{"system":"sec-edgar","filing":"0000950170-24-028822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024028822/ownership.xml","form_type":"4"}},{"id":1586034,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-03-08T17:59:02.000Z","date":"2024-03-06","kind":"exercise","planned":false,"acquired":true,"shares":40712,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1091021,"source":{"system":"sec-edgar","filing":"0000950170-24-028822","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024028822/ownership.xml","form_type":"4"}},{"id":1594243,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Restricted Stock Units","published_at":"2024-03-05T19:02:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":104909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 1, 2024, the reporting person was granted 104,909 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 1, 2024, the reporting person was granted 104,909 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":104909,"derivative":{"underlying":"Common Stock","underlying_shares":104909},"source":{"system":"sec-edgar","filing":"0000950170-24-026529","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024026529/ownership.xml","form_type":"4"}},{"id":1614626,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-27T19:59:36.000Z","date":"2024-02-23","kind":"exercise","planned":true,"acquired":false,"shares":22590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22590},"source":{"system":"sec-edgar","filing":"0000950170-24-021568","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021568/ownership.xml","form_type":"4"}},{"id":1614625,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-27T19:59:36.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":12462,"price":70.11,"value":873710.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.71 to $70.625, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1050309,"source":{"system":"sec-edgar","filing":"0000950170-24-021568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021568/ownership.xml","form_type":"4"}},{"id":1614624,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-27T19:59:36.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":9528,"price":69.45,"value":661719.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.79 to $69.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1062771,"source":{"system":"sec-edgar","filing":"0000950170-24-021568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021568/ownership.xml","form_type":"4"}},{"id":1614623,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-27T19:59:36.000Z","date":"2024-02-26","kind":"sale","planned":true,"acquired":false,"shares":600,"price":68.39,"value":41034.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.71 to $68.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1072299,"source":{"system":"sec-edgar","filing":"0000950170-24-021568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021568/ownership.xml","form_type":"4"}},{"id":1614622,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-27T19:59:36.000Z","date":"2024-02-23","kind":"exercise","planned":true,"acquired":true,"shares":22590,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":1072899,"source":{"system":"sec-edgar","filing":"0000950170-24-021568","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024021568/ownership.xml","form_type":"4"}},{"id":1658203,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-05T18:10:42.000Z","date":"2024-02-02","kind":"sale","planned":true,"acquired":false,"shares":17450,"price":67.42,"value":1176479.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.11 to $67.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1050309,"source":{"system":"sec-edgar","filing":"0000950170-24-011398","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024011398/ownership.xml","form_type":"4"}},{"id":1658202,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-05T18:10:42.000Z","date":"2024-02-02","kind":"sale","planned":true,"acquired":false,"shares":16435,"price":66.7,"value":1096214.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.11 to $67.1029, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1067759,"source":{"system":"sec-edgar","filing":"0000950170-24-011398","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024011398/ownership.xml","form_type":"4"}},{"id":1658201,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-02-05T18:10:42.000Z","date":"2024-02-01","kind":"grant","planned":true,"acquired":true,"shares":33885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issued upon the vesting of performance stock units."}],"balance_after":1084194,"source":{"system":"sec-edgar","filing":"0000950170-24-011398","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024011398/ownership.xml","form_type":"4"}},{"id":1676063,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-18T19:47:15.000Z","date":"2024-01-18","kind":"exercise","planned":true,"acquired":false,"shares":67917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested."}],"balance_after":8638,"derivative":{"exercise_price":16.86,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":67917},"source":{"system":"sec-edgar","filing":"0000950170-24-005557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024005557/ownership.xml","form_type":"4"}},{"id":1676062,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-18T19:47:15.000Z","date":"2024-01-17","kind":"exercise","planned":true,"acquired":false,"shares":48084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested."}],"balance_after":76555,"derivative":{"exercise_price":16.86,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":48084},"source":{"system":"sec-edgar","filing":"0000950170-24-005557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024005557/ownership.xml","form_type":"4"}},{"id":1676061,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-18T19:47:15.000Z","date":"2024-01-16","kind":"exercise","planned":true,"acquired":false,"shares":75361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option was granted on June 30, 2014 with an exercise price of $16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested."}],"balance_after":124639,"derivative":{"exercise_price":16.86,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":75361},"source":{"system":"sec-edgar","filing":"0000950170-24-005557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024005557/ownership.xml","form_type":"4"}},{"id":1676060,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":50018,"kind":"person","name":"Mates Sharon","position":1,"cik":"0001585699","reported_name":"Mates Sharon","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President & CEO"}}],"security":"Common Stock","published_at":"2024-01-18T19:47:15.000Z","date":"2024-01-18","kind":"sale","planned":true,"acquired":false,"shares":320,"price":66.25,"value":21200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 14, 2023 and amended on June 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.0143 to $66.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1050309,"source":{"system":"sec-edgar","filing":"0000950170-24-005557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1567514/000095017024005557/ownership.xml","form_type":"4"}}],"next_cursor":"2024-01-18T19:47:15.000000Z,1676060"}